|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.75 EUR | +0.19% |
|
+2.09% | +17.51% |
| 12-04 | Grifols achieves self-sufficiency in plasma-derived medicines in Egypt | RE |
| 12-03 | European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 7.58B | |||||
| 74.16B | |||||
| 59.32B | |||||
| 53.15B | |||||
| 52.8B | |||||
| 26.7B |
- Stock Market
- Equities
- GRF Stock
- Charts Grifols, S.A.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition